Furthermore, we identified here, for the first time, niclosamide inhibits both HuR nucleo-cytoplasmic translocation and PD-L1 glycosylation that niclosamide can improve the anti-PD-1 immunotherapy efficacy in syngeneic murine breast and lung cancer models. Here, ELAVL1 is linked to lung carcinoma.